Related references
Note: Only part of the references are listed.Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial
Claire N. Harrison et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study
Francesco Passamonti et al.
LANCET HAEMATOLOGY (2022)
Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations
Monia Marchetti et al.
Lancet Haematology (2022)
European LeukemiaNet Response Predicts Disease Progression but Not Thrombosis in Polycythemia Vera
Douglas Tremblay et al.
HEMASPHERE (2022)
Polycythemia vera: historical oversights, diagnostic details, and therapeutic views
Ayalew Tefferi et al.
LEUKEMIA (2021)
Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis
Lukas Ronner et al.
BLOOD (2020)
Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study
Jean-Jacques Kiladjian et al.
LANCET HAEMATOLOGY (2020)
Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial
Martin Griesshammer et al.
ANNALS OF HEMATOLOGY (2018)
From leeches to personalized medicine: evolving concepts in the management of polycythemia vera
Alessandro M. Vannucchi
HAEMATOLOGICA (2017)
From leeches to personalized medicine: evolving concepts in the management of polycythemia vera
Alessandro M. Vannucchi
HAEMATOLOGICA (2017)
Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study
Francesco Passamonti et al.
LANCET ONCOLOGY (2017)
Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera
Alberto Alvarez-Larran et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Characteristics and treatment of polycythemia vera patients in clinical practice: a multicenter chart review on 1476 individuals in Germany
Kathleen Jentsch-Ullrich et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2016)
Symptomatic Profiles of Patients leWith Polycythemia Vera: Implications of Inadequately Controlled Disease
Holly Geyer et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Cohort Profile: The Framingham Heart Study (FHS): overview of milestones in cardiovascular epidemiology
Connie W. Tsao et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2015)
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
Alessandro M. Vannucchi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project
Giovanni Barosi et al.
BLOOD (2013)
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN
Elisabetta Antonioli et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera
Alberto Alvarez-Larran et al.
BLOOD (2012)
A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process
Giovanni Barosi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference
Giovanni Barosi et al.
BLOOD (2009)
Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment
G. Barosi et al.
LEUKEMIA (2008)
Vascular and neoplastic risk in a large cohort of patients with polycythemia vera
R Marchioli et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Share Paper
